Abstract
In patients with Wilson's disease (WD), depression is a frequent psychiatric symptom. In vivo neuroimaging studies suggest that depression and other neuropsychiatric disorders are associated with central serotonergic deficits. However, in vivo measurements of serotonergic neurotransmission have not until now been performed in patients with this copper deposition disorder. The present prospective study revealed that depressive symptomatology is related to an alteration of presynaptic serotonin transporters (SERT) availability as measured by [123I]-2beta-carbomethoxy-3beta-(iodophenyl)tropane ([123I]beta-CIT) and high-resolution single-photon emission computed tomography (SPECT). SERT imaging with [123I]beta-CIT-SPECT could therefore become a useful tool for diagnosis and therapy monitoring in depressed WD patients.
MeSH terms
-
Adult
-
Brain / diagnostic imaging
-
Brain / metabolism
-
Brain / physiopathology
-
Brain Mapping
-
Carrier Proteins / metabolism*
-
Cocaine / analogs & derivatives*
-
Depressive Disorder / diagnostic imaging
-
Depressive Disorder / etiology*
-
Depressive Disorder / metabolism*
-
Female
-
Hepatolenticular Degeneration / complications*
-
Hepatolenticular Degeneration / metabolism*
-
Hepatolenticular Degeneration / psychology
-
Humans
-
Iodine Radioisotopes
-
Male
-
Membrane Glycoproteins / metabolism*
-
Membrane Transport Proteins*
-
Middle Aged
-
Nerve Tissue Proteins*
-
Neuropsychological Tests
-
Presynaptic Terminals / diagnostic imaging
-
Presynaptic Terminals / metabolism
-
Radioligand Assay
-
Serotonin Plasma Membrane Transport Proteins
-
Surveys and Questionnaires
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Carrier Proteins
-
Iodine Radioisotopes
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
SLC6A4 protein, human
-
Serotonin Plasma Membrane Transport Proteins
-
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
-
Cocaine